Monday, June 27, 2016 9:18:18 AM
One risk for NNVC from a declining stock price is removal from the New York/AMEX Small cap board. With market Cap now below 100 million a decline in price below 1.00 could trigger a review by the listing committee and being put on a watch-list.
It's been sometime since I worked on the AMEX floor - this was prior to the merger with the NYSE to form the small cap board. So the rules may have changed. There was a listing committee charged with the job of determining if candidates wanting listing met the criteria for initial listing. This minimum price requirement was the reason for the reverse split ( 1 for 3.5) undertaken by NNVC several years ago.
The requirements for getting listed are more stringent than for remaining listed, but there are indeed requirements to remain listed.
You can check them out here
http://venturelawcorp.com/nyse-mkt-listing-requirements/
When a stock loses its listing it means banishment to the pink-sheets. That changes a lot for a company and not in a good way. I believe NNVC understands this and will do everything they can to prevent it - even if it means buying by insiders.
New capital raises by a pink-sheet company are next to impossible on reasonable terms.
Trendliner
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM